A New Hope for Diabetic Peripheral Neuropathic Pain: Third-Generation Calcium ChannelModulator Approved in China
BEIJING, August 22,2024 – Diabetic peripheral neuropathic pain (DPNP), a debilitating complication of diabetes, is a growing concern globally as the prevalence of diabetescontinues to rise. DPNP can significantly impact a patient’s quality of life, causing severe pain, sleep disturbances, and emotional distress.
Whilethe treatment of DPNP aims to alleviate pain, improve functionality, enhance quality of life, and reduce recurrence, finding effective and safe treatment options has been a significant challenge for medical professionals.
DPNP is a hidden disease, explainedProfessor Guo Xiaohui from the Department of Endocrinology at Peking University First Hospital. In the early stages of type 2 diabetes, microvascular and nerve damage are minimal. However, as the disease progresses, these damages become more prominent,often going unnoticed until they are already significant. Once nerve damage occurs, it is largely irreversible, and patients face a long-term struggle with poor blood sugar control, worsening vascular and nerve damage.
Professor Wang Guang, from the Department of Endocrinology at Beijing Chaoyang Hospital, affiliated with Capital Medical University, highlighted the challengesfaced in managing chronic pain like DPNP. Over 70% of DPNP patients experience moderate to severe persistent pain, leading to sleeplessness, decreased quality of life, and emotional disorders. Early diagnosis is crucial, as it allows for timely disease management and pain relief, minimizing the impact on daily life.
The limited availability of effective and safe treatment options for DPNP has left a significant unmet need in clinical practice. However, a recent breakthrough has brought new hope to patients suffering from this debilitating condition.
In June 2024, the National Medical Products Administration (NMPA) of China approvedthe third-generation calcium channel modulator, DS5565-A-A315, marketed as DeriJing, for the treatment of DPNP in adults. This approval marks a significant milestone in the fight against DPNP, offering a new therapeutic avenue for patients.
Clinical trials conducted withDS5565-A-A315 have demonstrated statistically significant improvements in pain relief for patients with DPNP. The drug also showed notable improvements in overall pain perception, sleep quality, and overall quality of life for patients.
The availability of this third-generation calcium channel modulator is anew ray of hope for DPNP patients, stated Professor Guo. The clinical trial results have confirmed its effectiveness in alleviating pain, and we are optimistic that it will benefit a large number of Chinese patients.
The approval of DeriJing is a testament to the ongoing efforts in China to develop innovative treatments for chronicdiseases. With this new therapeutic option, patients with DPNP can now look forward to a future with less pain, better sleep, and improved quality of life.
【来源】http://www.chinanews.com/life/2024/08-22/10273284.shtml
Views: 1